AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32439737 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for predictors of DM
Number of subjects: 992
Study 32440228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 20 μg/Drospirenone 3 mg
Number of subjects: 186
Study 32440228 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment SF-36v2 scores
Number of subjects: 186
Study 32440613 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32440638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 0
Study 32440638 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia during pregnancy
Number of subjects: 0
Study 32440790 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin and fever
Number of subjects: 73
Study 32440790 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble CD25
Number of subjects: 73
Study 32440790 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-malignancy-associated HLH
Number of subjects: 73
Study 32440790 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignancy-associated HLH
Number of subjects: 73
Study 32441114 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated major adverse cardiovascular events
Number of subjects: 16485
Study 32441114 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-serious adverse events
Number of subjects: 16485
Study 32441114 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Dictionary for Regulatory Activities terms
Number of subjects: 16485
Study 32441114 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated deaths
Number of subjects: 16485
Study 32441114 — intervention group
Group type: EXPERIMENTAL
Intervention: Site assessment of cardiovascular death
Number of subjects: 16485
Study 32441582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1120
Study 32441892 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose apatinib (500 mg or 250 mg per day)
Number of subjects: 747
Study 32442144 — intervention group
Group type: EXPERIMENTAL
Intervention: InCharge Health app
Number of subjects: 8
Study 32442144 — intervention group
Group type: EXPERIMENTAL
Intervention: HU Toolbox app
Number of subjects: 8
Study 32442254 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated CABG
Number of subjects: 2397
Study 32442603 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-bore sheaths (>21F outer diameter)
Number of subjects: 360
Study 32442603 — intervention group
Group type: COMPARATOR
Intervention: Small-bore sheaths (≤21F outer diameter)
Number of subjects: 360
Study 32442637 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated segmentation and surface extraction pipeline for T1-weighted neuroimaging data
Number of subjects: 0
Study 32442637 — intervention group
Group type: COMPARATOR
Intervention: Comparator software solutions
Number of subjects: 0
Study 32442638 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased network integration in older adults during high difficulty working memory tasks
Number of subjects: 0
Study 32442638 — intervention group
Group type: COMPARATOR
Intervention: Decreased network integration in younger adults during high difficulty working memory tasks
Number of subjects: 0
Study 32442638 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher WM capacity in older adults
Number of subjects: 0
Study 32442785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rigosertib (140 mg twice daily, 280 mg twice daily, or 840 mg/day [560 mg morning/280 mg evening]) for 3 weeks of a 4-week cycle
Number of subjects: 18
Study 32442785 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral azacitidine (75 mg/m2)
Number of subjects: 18
Study 32443037 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD group
Number of subjects: 219
Study 32443037 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD with erosive esophagitis
Number of subjects: 219
Study 32443037 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 219
Study 32443041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) performed between 2.5 and 3.5 months of age.
Number of subjects: 38
Study 32443041 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal OGTT defined as early hyperglycaemia (>1.8 g/L until 30 minutes; >1.7 g/L between 30 minutes and 2 hours; and >1.4 g/L between 2 and 3 hours) and/or late hypoglycaemia (<0.6 g/L after 2 hours).
Number of subjects: 38
Study 32443041 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for potential dumping syndrome (DS) using OGTT around 3 months of age.
Number of subjects: 38
Study 32443148 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern ART
Number of subjects: 22
Study 32443148 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic interventions
Number of subjects: 22
Study 32444192 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct venous inoculation (DVI) of PfSPZ Vaccine (0.5 mL)
Number of subjects: 511
Study 32444192 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct venous inoculation (DVI) of PfSPZ Vaccine
Number of subjects: 511
Study 32444241 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin/micronutrients supplement
Number of subjects: 0
Study 32444411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation with ferric maltol
Number of subjects: 0
Study 32444417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib plus Olaparib (Olaparib 300 mg twice daily + Cediranib 20 mg once daily)
Number of subjects: 34
Study 32444431 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of vitamin K2
Number of subjects: 2987
Study 32444431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 intake
Number of subjects: 2987
Study 32444455 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 606
Study 32444455 — intervention group
Group type: COMPARATOR
Intervention: No statin use (Control)
Number of subjects: 606
Study 32444557 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperament Harm Avoidance
Number of subjects: 333
Study 32444557 — intervention group
Group type: EXPERIMENTAL
Intervention: Character Self-Directedness
Number of subjects: 333
Study 32444996 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake, source and distribution
Number of subjects: 130
Study 32444996 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intakes
Number of subjects: 130
Study 32445415 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation for patients with anxiety symptoms
Number of subjects: 0
Study 32445415 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation for patients with depression symptoms
Number of subjects: 0
Study 32445848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale scores
Number of subjects: 348
Study 32445848 — intervention group
Group type: EXPERIMENTAL
Intervention: Average pain intensity
Number of subjects: 348
Study 32445848 — intervention group
Group type: EXPERIMENTAL
Intervention: Average pain intensity in remitting trajectory
Number of subjects: 348
Study 32445848 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function
Number of subjects: 348
Study 32445848 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative average pain intensity scores
Number of subjects: 348
Study 32445848 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical function scores
Number of subjects: 348
Study 32445848 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged hospitalization, smoking, and preoperative opioid prescriptions
Number of subjects: 348
Study 32446108 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure + Placebo (PE + PLB)
Number of subjects: 0
Study 32446108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline + Prolonged Exposure (SERT + PE)
Number of subjects: 0
Study 32446108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline + Enhanced Medication Management (SERT + EMM)
Number of subjects: 0
Study 32446108 — intervention group
Group type: COMPARATOR
Intervention: Combat controls
Number of subjects: 0
Study 32446407 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory cell-based medicinal products (CBMPs) in CTG trials
Number of subjects: 104
Study 32446407 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care immunosuppression in RGT (basiliximab, tapered steroids, mycophenolate mofetil, tacrolimus)
Number of subjects: 104
Study 32446407 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined adverse event data from CTG trials
Number of subjects: 104
Study 32446407 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG trials
Number of subjects: 104
Study 32446494 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety
Number of subjects: 144
Study 32446494 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 144
Study 32446494 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental quality of life
Number of subjects: 144
Study 32446494 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on family
Number of subjects: 144
Study 32446494 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect sizes
Number of subjects: 144
Study 32446716 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective beta-blockers (NSBBs)
Number of subjects: 38
Study 32447411 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0
Study 32447411 — intervention group
Group type: COMPARATOR
Intervention: Melanoma targeted radionuclide therapy (TRT)
Number of subjects: 0
Study 32447421 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-11047, 60-min intravenous infusions, doses ranging from 50 to 750 mg, administered on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 46
Study 32447545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (200 mg)
Number of subjects: 0
Study 32447545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (100 mg)
Number of subjects: 0
Study 32447545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (50 mg)
Number of subjects: 0
Study 32447545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32447550 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-H (visual hallucinations)
Number of subjects: 82
Study 32447550 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-I (visual illusions)
Number of subjects: 82
Study 32447743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 2778
Study 32447743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2778
Study 32447743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (during 'at-risk' period)
Number of subjects: 2778
Study 32447743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during 'at-risk' period)
Number of subjects: 2778
Study 32447743 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner pregnancies (female partners of cladribine-treated male patients)
Number of subjects: 2778
Study 32448149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 1486
Study 32448149 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular strength
Number of subjects: 1486
Study 32448149 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition
Number of subjects: 1486
Study 32448233 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes screening and management intervention
Number of subjects: 36
Study 32448349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 397
Study 32448349 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c (HbA1c)
Number of subjects: 397
Study 32448349 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour plasma glucose (2-h PG) after a 75-g oral glucose tolerance test
Number of subjects: 397
Study 32448380 — intervention group
Group type: EXPERIMENTAL
Intervention: HLH-2004 criteria with a cutoff of 4 fulfilled criteria
Number of subjects: 2623
Study 32448380 — intervention group
Group type: EXPERIMENTAL
Intervention: HScore with a cutoff of 168
Number of subjects: 2623
Study 32448380 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted HLH-2004 criteria cutoffs (hyperferritinemia to 3000 μg/L and fever to 38.2 °C)
Number of subjects: 2623
Study 32448380 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of fulfilled HLH-2004 criteria
Number of subjects: 2623
Study 32448380 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HScore
Number of subjects: 2623
Study 32448380 — intervention group
Group type: EXPERIMENTAL
Intervention: HScore cutoff of 168
Number of subjects: 2623
Study 32448795 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing with Pap
Number of subjects: 50000
Study 32448795 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage techniques (not specified)
Number of subjects: 50000
Study 32448808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 20
Study 32448902 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 12 mg/kg twice daily (administered after crushing)
Number of subjects: 0
Study 32448949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 9
Study 32449002 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 542
Study 32449053 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intubation (before H8 following vasopressor onset)
Number of subjects: 859
Study 32449053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative intubation during ICU stay
Number of subjects: 859
Study 32449053 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis parameters associated with early intubation
Number of subjects: 859
Study 32449053 — intervention group
Group type: EXPERIMENTAL
Intervention: Global R-square of the model
Number of subjects: 859
Study 32449053 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological, respiratory and hemodynamic parameters
Number of subjects: 859
Study 32449053 — intervention group
Group type: EXPERIMENTAL
Intervention: Center effect
Number of subjects: 859
Study 32449053 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 859
Study 32449068 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Position (PP) sessions
Number of subjects: 103
Study 32449201 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive sweeteners (NNS)
Number of subjects: 979
Study 32449223 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk lymph node ratio (LNR) > 7.6%
Number of subjects: 245
Study 32449223 — intervention group
Group type: COMPARATOR
Intervention: Low-risk lymph node ratio (LNR) ≤ 7.6%
Number of subjects: 245
Study 32449223 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk LNR
Number of subjects: 245
Study 32449445 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who could see clearly from 29 to 33 cm
Number of subjects: 500
Study 32449684 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (CBT) plus Treatment-As-Usual (TAU)
Number of subjects: 120
Study 32449684 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Exercise plus Treatment-As-Usual (TAU)
Number of subjects: 120
Study 32449684 — intervention group
Group type: COMPARATOR
Intervention: Wait-listing to receive Treatment-As-Usual (TAU) only
Number of subjects: 120
Study 32449690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone condition (Monsenso mDiary mobile app)
Number of subjects: 80
Study 32449690 — intervention group
Group type: COMPARATOR
Intervention: Pen-and-paper condition
Number of subjects: 80
Study 32449927 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized criteria (PAC >20 ng/dL, PRC <2.5 μIU/mL, hypokalemia)
Number of subjects: 518
Study 32449927 — intervention group
Group type: COMPARATOR
Intervention: Guideline criteria
Number of subjects: 518
Study 32449927 — intervention group
Group type: COMPARATOR
Intervention: SIT or FST as confirmatory tests
Number of subjects: 518
Study 32449975 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease (NHS)
Number of subjects: 45
Study 32450238 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux (GER)
Number of subjects: 131
Study 32450238 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid GER
Number of subjects: 131
Study 32450238 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenogastroesophageal reflux (DGER)
Number of subjects: 131
Study 32450238 — intervention group
Group type: COMPARATOR
Intervention: No reflux
Number of subjects: 131
Study 32450725 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus nab-paclitaxel
Number of subjects: 0
Study 32450725 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 0
Study 32450725 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination studies with chemotherapy
Number of subjects: 0
Study 32450820 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tool to identify high-risk individuals for prolonged sickness absence due to musculoskeletal disorders
Number of subjects: 600
Study 32450820 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life, health care utilization, and costs across different risk profiles
Number of subjects: 600
Study 32450820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickness absence data from NAV registry
Number of subjects: 600
Study 32450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage fluid (BAL)
Number of subjects: 18
Study 32450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour tissue
Number of subjects: 18
Study 32450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritumoural tissue
Number of subjects: 18
Study 32450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung microbiota analysis
Number of subjects: 18
Study 32450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower lobe (LL) samples
Number of subjects: 18
Study 32450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung tissues
Number of subjects: 18
Study 32450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota composition
Number of subjects: 18
Study 32450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Firmicutes in LL
Number of subjects: 18
Study 32450874 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE Program (Community Outreach and Patient Empowerment)
Number of subjects: 173
Study 32450874 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study 32451120 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 400 mg once daily for CYP2B6 516 GG genotype
Number of subjects: 360
Study 32451120 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 300 mg once daily for CYP2B6 516 GT genotype
Number of subjects: 360
Study 32451120 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 100 mg once daily for CYP2B6 516 TT genotype
Number of subjects: 360
Study 32451120 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 800 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 GG genotype
Number of subjects: 360
Study 32451120 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 GT genotype
Number of subjects: 360
Study 32451120 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 200 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 TT genotype
Number of subjects: 360
Study 32451120 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin co-administration
Number of subjects: 360
Study 32451223 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 2437
Study 32451223 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI (Architect)
Number of subjects: 2437
Study 32451223 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI (Centaur)
Number of subjects: 2437
Study 32451495 — intervention group
Group type: EXPERIMENTAL
Intervention: BL-8040 and pembrolizumab
Number of subjects: 37
Study 32451615 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab beta 150 mg subcutaneously every 4 weeks for up to 6 years
Number of subjects: 410
Study 32451615 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab beta treatment
Number of subjects: 410
Study 32451952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir plus Ribavirin for 12 weeks
Number of subjects: 26
Study 32451952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir plus Ribavirin
Number of subjects: 26
Study 32452392 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with patients diagnosed with GTPS
Number of subjects: 10
Study 32452462 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative reactivity
Number of subjects: 291
Study 32452462 — intervention group
Group type: COMPARATOR
Intervention: Positive reactivity
Number of subjects: 291
Study 32452555 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting the administration of antenatal corticosteroids (ACS)
Number of subjects: 100705
Study 32453126 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) induction
Number of subjects: 13
Study 32453169 — intervention group
Group type: EXPERIMENTAL
Intervention: Labour epidural analgesia
Number of subjects: 651
Study 32453169 — intervention group
Group type: COMPARATOR
Intervention: No labour epidural analgesia
Number of subjects: 651
Study 32453169 — intervention group
Group type: EXPERIMENTAL
Intervention: Predelivery anxiety and depression
Number of subjects: 651
Study 32453217 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study 32453485 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sarilumab
Number of subjects: 322
Study 32453485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous/subcutaneous tocilizumab
Number of subjects: 322
Study 32453615 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode of delivery
Number of subjects: 106
Study 32453615 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding status
Number of subjects: 106
Study 32453615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 106